V2X Lands $170 Million DEA Contract To Combat Drug Trafficking; Stock Gains

Comments
Loading...
Zinger Key Points
  • V2X secures $170M DEA contract to support fleet of over 100 aircraft, bolstering anti-drug trafficking efforts.
  • CEO Jeremy Wensinger emphasizes V2X's role in delivering impactful solutions to safeguard national security.

V2X, Inc. VVX shares are trading higher premarket on Monday. The company secured a $170 million contract to support the Drug Enforcement Administration’s (DEA) fleet of over 100 aircraft.

This award highlights V2X’s dedication to advancing the DEA’s mission in combating drug trafficking and safeguarding national security.

Jeremy C. Wensinger, President and CEO of V2X, said, “V2X has consistently demonstrated a complete understanding of the DEA’s mission, and the flexibility required to support its special mission aircraft and pilot development.”

“This award reflects the trust placed in our team to deliver high-impact solutions that empower the DEA to combat drug trafficking and safeguard national security.”

Earlier this month, V2X formed a strategic joint venture with Parsons Corporation to pursue the National Science Foundation’s Antarctica Science and Engineering Support Contract (ASESC) with a ceiling value of $8 billion.

This joint venture will provide world-class scientific research support for the U.S. Antarctic Program over the next two decades.

Recently, V2X opened its new corporate headquarters in Reston, Virginia. The new location supports V2X’s presence in a region that serves as a defense, technology, and aerospace industry hub and will advance V2X’s missions.

Price Action: VVX shares are up 4.15% at $48.93 premarket at the last check Monday.

Read Next:

Overview Rating:
Speculative
37.5%
Technicals Analysis
66
0100
Financials Analysis
20
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!